Hyde Park Capital Renders Fairness Opinion To Unilens Vision
Tampa, Florida - September 03, 2015 - Hyde Park Capital Advisors, LLC (“Hyde Park Capital”) is pleased to announce it has rendered a fairness opinion to the Board of Directors of Unilens Vision Inc. (“Unilens”), a specialty optical contact lens company, in connection with its sale to Valeant Pharmaceuticals International.
Michael J. Pecora, Chairman of the Board, Chief Executive Officer and President of Unilens, stated, “We are pleased to sign a definitive agreement with Valeant, which creates immediate value for our stockholders. The combination of Unliens’ world class technology and its leading customized lens business with Valeant will create a strong portfolio of products enhancing our commitment to providing the best possible visual outcomes throughout the optical industry. In the coming months we will be working closely with the Valeant team to ensure a smooth transaction.”
“We are pleased to have assisted in this transaction through the completion of a fairness opinion to the Board of Directors,” said Keith Hodgdon. “This transaction highlights Hyde Park Capital’s expertise in the healthcare sector and its proficiency in providing investment banking advice and valuation analysis to premier middle market companies, such as Unilens.”
About Unilens Vision Inc. (OTCQX:UVIC)
Established in 1989, Unilens Vision Inc., through its wholly-owned subsidiary Unilens Corp., USA, located in Largo, Florida, and its wholly-owned subsidiary Unilens Vision Sciences Inc., develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue® brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company’s common stock is listed on the OTCQX under the symbol “UVIC”.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
About Hyde Park Capital
Hyde Park Capital is a middle-market investment banking firm specializing in mergers and acquisitions and capital raising for public and private companies. Our senior bankers have extensive investment banking experience executing merger & acquisition engagements, including purchase and sale of company assignments, recapitalizations, financial advisory, fairness opinions and raising growth capital and acquisition financing for companies, including equity, mezzanine and senior debt. Hyde Park Capital has broad experience across multiple industries and a specific focus on healthcare, technology, business and financial services. As one of the most active investment banking firms in Florida and the Southeast, our professionals have advised on more than 300 corporate investment banking transactions totaling more than $10 billion in transaction value. We are headquartered in Tampa, Florida and are a member of FINRA and SIPC. For additional information about Hyde Park Capital, visit www.hydeparkcapital.com or call (813) 383-0202.